Last reviewed · How we verify
Mosunetuzumab in combination with Zanubrutinib
Mosunetuzumab in combination with Zanubrutinib is a Small molecule drug developed by Fondazione Italiana Linfomi - ETS. It is currently in Phase 2 development. Also known as: LUNSUMIO in combination with BRUSINKA.
At a glance
| Generic name | Mosunetuzumab in combination with Zanubrutinib |
|---|---|
| Also known as | LUNSUMIO in combination with BRUSINKA |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (PHASE1, PHASE2)
- Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mosunetuzumab in combination with Zanubrutinib CI brief — competitive landscape report
- Mosunetuzumab in combination with Zanubrutinib updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI
Frequently asked questions about Mosunetuzumab in combination with Zanubrutinib
What is Mosunetuzumab in combination with Zanubrutinib?
Mosunetuzumab in combination with Zanubrutinib is a Small molecule drug developed by Fondazione Italiana Linfomi - ETS.
Who makes Mosunetuzumab in combination with Zanubrutinib?
Mosunetuzumab in combination with Zanubrutinib is developed by Fondazione Italiana Linfomi - ETS (see full Fondazione Italiana Linfomi - ETS pipeline at /company/fondazione-italiana-linfomi-ets).
Is Mosunetuzumab in combination with Zanubrutinib also known as anything else?
Mosunetuzumab in combination with Zanubrutinib is also known as LUNSUMIO in combination with BRUSINKA.
What development phase is Mosunetuzumab in combination with Zanubrutinib in?
Mosunetuzumab in combination with Zanubrutinib is in Phase 2.
Related
- Manufacturer: Fondazione Italiana Linfomi - ETS — full pipeline
- Also known as: LUNSUMIO in combination with BRUSINKA